Jones JO - Search Results

1

RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. Pal SK, et al. Among authors: jones jo. Mol Cancer Res. 2015 Jan;13(1):130-7. doi: 10.1158/1541-7786.MCR-14-0352. Epub 2014 Sep 2. Mol Cancer Res. 2015. PMID: 25183163 Free PMC article.

2

Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree.

Bergerot P, Agarwal N, Pal SK, Jones J. Bergerot P, et al. Clin Cancer Res. 2017 Nov 1;23(21):6381-6383. doi: 10.1158/1078-0432.CCR-17-2039. Epub 2017 Sep 14. Clin Cancer Res. 2017. PMID: 28912138

3

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C. Pal SK, et al. Among authors: jones jo. Urol Oncol. 2013 Nov;31(8):1826-31. doi: 10.1016/j.urolonc.2012.04.007. Epub 2012 May 17. Urol Oncol. 2013. PMID: 22608544 Free PMC article.

4

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Pal SK, et al. Eur Urol. 2017 Oct;72(4):557-564. doi: 10.1016/j.eururo.2017.03.046. Epub 2017 Apr 14. Eur Urol. 2017. PMID: 28413127

5

The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. Bergerot PG, et al. Curr Treat Options Oncol. 2018 Feb 20;19(2):10. doi: 10.1007/s11864-018-0530-4. Curr Treat Options Oncol. 2018. PMID: 29464405 Review.

6

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.

Pal SK, Hossain DM, Zhang Q, Frankel PH, Jones JO, Carmichael C, Ruel C, Lau C, Kortylewski M. Pal SK, et al. Among authors: jones jo. J Urol. 2015 Apr;193(4):1114-21. doi: 10.1016/j.juro.2014.09.110. Epub 2014 Oct 5. J Urol. 2015. PMID: 25286010

7

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Pal SK, Agarwal N, Jones JO. Pal SK, et al. Among authors: jones jo. Cancer. 2015 Sep 15;121(18):3190-2. doi: 10.1002/cncr.29454. Epub 2015 May 14. Cancer. 2015. PMID: 25980931 Free article. No abstract available.

8

Vitamin K epoxide reductase expression and prostate cancer risk.

Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO. Tew BY, et al. Among authors: jones jo. Urol Oncol. 2017 Mar;35(3):112.e13-112.e18. doi: 10.1016/j.urolonc.2016.10.020. Epub 2016 Nov 23. Urol Oncol. 2017. PMID: 27889279

9

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO. Pal SK, et al. Among authors: jones jo. Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19. Cancer. 2018. PMID: 29266182 Free article.

10

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer.

Hill A, Cristea M, He M, Frankel P, Neuhausen S, Pal SK, Jones JO. Hill A, et al. Among authors: jones jo. J Cancer Res Ther Oncol. 2019 Mar;7(1):103. doi: 10.17303/jcrto.2019.7.103. Epub 2019 May 7. J Cancer Res Ther Oncol. 2019. PMID: 34926721 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters